Stock Analysis
Definium Therapeutics, Inc. (DFTX) Stock Analysis
Definium Therapeutics, Inc. (DFTX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Definium Therapeutics, Inc. (DFTX) currently has an AIQ Score of 59/100, indicating a neutral setup. Momentum is the strongest factor at 64/100. Risk is the weakest current factor at 44/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
DFTX at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $32.08 |
| AIQ Score | 59/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $4.36B |
| P/E Ratio (TTM) | -10.59 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$0.37 |
| Revenue (Q3 FY2026) | $0 |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.14 |
| Volume | 778.19K |
| 52-week range | $10.46-$49.70 |
| RSI 14 | 41.55 |
| 50-Day SMA | $36.07 |
| 200-Day SMA | $30.43 |
| Analyst Price Target | $75.50 |
| Next Earnings | Feb 25, 2027 |
DFTXDefinium Therapeutics, Inc.
Healthcare / Biotechnology
Relative Leader / Watch
Sector Leader
Latest quote
- Momentum64
- Value—
- Quality60
- Risk resilience44
- Sentiment—
DFTX Stock Analysis Summary
Definium Therapeutics, Inc. (DFTX) currently has an AIQ Score of 59/100, indicating a neutral setup. Momentum is the strongest factor at 64/100. Risk resilience is the weakest current factor at 44/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, DFTX has AIQ Score of 59/100 with Momentum base of 64/100 and fading Risk resilience at 44/100. Wait for component alignment before adding exposure.
Momentum (64/100) leads while Risk resilience (44/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -2.79% stock move · DFTX classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is DFTX Bullish or Bearish Right Now?
DFTX currently has a neutral overall setup. Momentum is the strongest factor at 64/100, while Risk Resilience is weakest at 44/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Analyst target implies +135.35% upside from the latest quote.
- - Risk Resilience is weak at 44/100.
- - Technical consensus has more sell votes than buy votes (35 vs 4).
Current Consensus
DFTX's Technical Analysis Consensus is currently Strong Sell, with 4 buy, 7 neutral, and 35 sell votes. DFTX's 14-day RSI is 41.55, which places the stock in a weaker momentum range. DFTX's beta is 1.14, indicating market sensitivity broadly in line with the market.
What Changed in DFTX?
The largest recent change in DFTX is Quality moving up by 3.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the DFTX Outlook?
The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
DFTX Decision Framework
Public evidence layers, setup checks, and risk context for Definium Therapeutics, Inc..
Definium Therapeutics, Inc. (DFTX) Stock Analysis
Definium Therapeutics, Inc. has an AIQ Score of 59/100 in a Neutral regime. Momentum is strongest at 64/100. Beta is 1.14, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | DFTX is in a Neutral AIQ regime with score 59/100. |
| Signal Conflict | The primary conflict is that momentum leads at 64/100 while risk lags at 44/100. |
| Factor Evidence | Momentum 64/100 · Quality 60/100 · Risk 44/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 64/100.
Momentum is 64/100 and RSI (14) is 41.6.
DFTX is in a Neutral regime at 59/100.
Risk factor is 44/100 with beta 1.14 and annual volatility 77.71%.
Current conflict: momentum leads at 64/100 while risk lags at 44/100.
DFTX Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
DFTX Fundamentals
DFTX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
DFTX Technical Analysis
DFTX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
DFTX Stock Catalysts
Track DFTX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
DFTX Dividend Analysis
DFTX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
DFTX Financial Data
DFTX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
DFTX Risk Analysis
DFTX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
DFTX Stock News
DFTX stock news, market tone, recent headlines, and catalyst context.
DFTX vs Biotechnology Peers
Current peer cohort: DFTX · DNTH · DYN · ELVN · ERAS. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| DFTX Current stock | 59/100 | — | 64/100 | 44/100 | 1.61 | 77.71% | Current |
| DNTH Dianthus Therapeutics, Inc. | 56/100 | — | 58/100 | 58/100 | 1.82 | 59.79% | DFTX vs DNTH |
| DYN Dyne Therapeutics, Inc. | 48/100 | — | 52/100 | 42/100 | 0.11 | 63.89% | DFTX vs DYN |
| ELVN Enliven Therapeutics, Inc. | 71/100 | — | 66/100 | 56/100 | 1.43 | 78.19% | DFTX vs ELVN |
| ERAS Erasca, Inc. | 61/100 | — | 67/100 | 39/100 | 2.29 | 102.70% | DFTX vs ERAS |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for DFTX: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching DFTX
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for DFTX
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
DFTX Stock FAQ
What is DFTX stock price today?
Definium Therapeutics, Inc.'s current stock price is $32.08. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is DFTX bullish or bearish right now?
DFTX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is DFTX's market cap?
DFTX's market cap is $4.36B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is DFTX's current P/E ratio?
DFTX's current P/E ratio is -10.59 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is DFTX's RSI?
DFTX's 14-day RSI is 41.55 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is DFTX above its 50-day and 200-day moving averages?
DFTX is -11.06% from its 50-day SMA and 5.43% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is DFTX's next earnings date?
DFTX's next earnings date is currently listed as Feb 25, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does DFTX pay a dividend?
DFTX's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.